Obesity and polycystic ovary syndrome
- PMID: 33460482
- DOI: 10.1111/cen.14421
Obesity and polycystic ovary syndrome
Abstract
The increased global prevalence of obesity over the last 40-years has driven a rise in prevalence of obesity-related co-morbidities, including polycystic ovary syndrome (PCOS). On a background of genetic susceptibility, PCOS often becomes clinically manifest following weight gain, commonly during adolescence. A common endocrinopathy affecting between 6%-10% of reproductive-age women, PCOS presents with the cardinal features of hyperandrogenism, reproductive and metabolic dysfunction. PCOS associates with insulin resistance, independently of (but amplified by) obesity. Insulin resistance in PCOS is characterized by abnormal post-receptor signalling within the phosphatidylinositol-kinase (PI3-K) pathway. Multiple factors (including most notably, weight gain) contribute towards the severity of insulin resistance in PCOS. Compensatory hyperinsulinaemia ensues, resulting in over-stimulation of the (intact) post-receptor mitogen-activated protein kinase (MAP-K) insulin pathway, with consequent implications for steroidogenesis and ovarian function. In this concise review, we explore the effects of weight gain and obesity on the pathogenesis of PCOS from the perspective of its three cardinal features of hyperandrogenism, reproductive and metabolic dysfunction, with a focus on the central mediating role of the insulin pathway. We also consider key lifestyle strategies for the effective management of obese and overweight women with PCOS.
Keywords: metabolism; obesity; polycystic ovary syndrome.
© 2021 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd.
Similar articles
-
Polycystic ovary syndrome: insight into pathogenesis and a common association with insulin resistance.Clin Med (Lond). 2016 Jun;16(3):262-6. doi: 10.7861/clinmedicine.16-3-262. Clin Med (Lond). 2016. PMID: 27251917 Free PMC article. Review.
-
Polycystic ovary syndrome: insight into pathogenesis and a common association with insulin resistance.Clin Med (Lond). 2015 Dec;15 Suppl 6:s72-6. doi: 10.7861/clinmedicine.15-6-s72. Clin Med (Lond). 2015. PMID: 26634686 Review.
-
Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies.Mol Metab. 2020 May;35:100937. doi: 10.1016/j.molmet.2020.01.001. Epub 2020 Feb 5. Mol Metab. 2020. PMID: 32244180 Free PMC article.
-
POLYCYSTIC OVARY SYNDROME: ORIGINS AND IMPLICATIONS: Polycystic ovary syndrome: an evolutionary metabolic adaptation.Reproduction. 2025 Mar 24;169(4):e250021. doi: 10.1530/REP-25-0021. Print 2025 Apr 1. Reproduction. 2025. PMID: 40080428 Review.
-
Management of polycystic ovary syndrome in childhood and adolescence.Horm Res Paediatr. 2010;74(5):372-5. doi: 10.1159/000320388. Epub 2010 Sep 22. Horm Res Paediatr. 2010. PMID: 20861609 Review.
Cited by
-
Low Serum 25-Hydroxyvitamin D Levels Are Associated With Hyperandrogenemia in Polycystic Ovary Syndrome: A Cross-Sectional Study.Front Endocrinol (Lausanne). 2022 May 2;13:894935. doi: 10.3389/fendo.2022.894935. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35586624 Free PMC article.
-
Assessment of metabolic syndrome in infertile women with polycystic ovary syndrome in a rural population of South India: A cross-sectional study.Int J Reprod Biomed. 2022 Apr 21;20(3):161-168. doi: 10.18502/ijrm.v20i3.10707. eCollection 2022 Mar. Int J Reprod Biomed. 2022. PMID: 35642189 Free PMC article.
-
Obesity-Related Hypogonadism in Women.Endocr Rev. 2024 Mar 4;45(2):171-189. doi: 10.1210/endrev/bnad027. Endocr Rev. 2024. PMID: 37559411 Free PMC article. Review.
-
Prenatal kisspeptin antagonist exposure prevents polycystic ovary syndrome development in prenatally-androgenized rats in adulthood: An experimental study.Int J Reprod Biomed. 2023 Mar 8;21(2):99-110. doi: 10.18502/ijrm.v21i2.12801. eCollection 2023 Feb. Int J Reprod Biomed. 2023. PMID: 37034298 Free PMC article.
-
Polycystic Ovary Syndrome Detection Machine Learning Model Based on Optimized Feature Selection and Explainable Artificial Intelligence.Diagnostics (Basel). 2023 Apr 21;13(8):1506. doi: 10.3390/diagnostics13081506. Diagnostics (Basel). 2023. PMID: 37189606 Free PMC article.
References
REFERENCES
-
- Jaacks LM, Vandevijvere S, Pan A, et al. The obesity transition: stages of the global epidemic. Lancet Diabetes Endocrinol. 2019;7(3):231-240.
-
- Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:88.
-
- Barber TM, McCarthy MI, Wass JA, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf). 2006;65(2):137-145.
-
- Saboor Aftab SA, Kumar S, Barber TM. The role of obesity and type 2 diabetes mellitus in the development of male obesity-associated secondary hypogonadism. Clin Endocrinol (Oxf). 2013;78(3):330-337.
-
- Barber TM, Hanson P, Weickert MO, Franks S. Obesity and Polycystic Ovary Syndrome: Implications for Pathogenesis and Novel Management Strategies. Clin Med Insights Reprod Health. 2019;13:1179558119874042.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical